Ani Pharmaceuticals Inc (ANIP) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ani Pharmaceuticals Inc  (NASDAQ: ANIP)


Ani Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Ani Pharmaceuticals Inc's ROI in the third quarter of 2026?
Ani Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 9.61 % in its third quarter of 2026, this is above ANIP's average return on investment of -6.64%.
Ani Pharmaceuticals Inc invested over the 12 months ending in its third quarter of 2026 $1,199 million

ROI has improved compared to 9.09% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 52 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 1030, from total ROI ranking in the second quarter of 2026 at 1338.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 8.36 % 7.04 % 13.05 % 20.04 % 29.57 %
Y / Y Net Income Change TTM 183.78 % - - - -
Investment (TTM) in Millions 1,239 1,210 1,182 1,162 1,138
Return On Investment (TTM) 9.61 % 9.09 % 8.03 % 6.97 % 3.67 %
ANIP's Overall Ranking # 1030 # 1338 # 1581 # 2683 # 2799
Seq. Investment Change TTM 2.16 % 2.27 % 2.04 % 1.63 % 0.92 %
Seq. Net Income Change TTM 8 % 15.68 % 17.63 % 93.09 % -
Net Income (TTM) in Millions 115 107 92 78 41

ANIP Company Profile >> Back to ANIP Roi Comparisons >> See Annual ANIP Return On Investment



Return On Investment ANIP's Ranking
Within: No.
Industry # 20
Sector # 53
Overall # 1030

Return On Investment Statistics
High Average Low
23.28 %
-6.64 %
-110.74 %
(Dec 31 2014)   (Dec 31 2011)







Financial Statements
Ani Pharmaceuticals Inc's III. Quarter Investments $ 1,239 Millions ANIP's Balance sheet
Ani Pharmaceuticals Inc's III. Quarter Income $ 35 Millions Quarterly ANIP's Income Statement
ANIP's Income by Division See ANIP's Income by Division


ANIP Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,162 1,090 759 661 684
Y / Y Investment Growth 6.63 % 43.62 % 14.88 % -3.42 % 78.78 %
Net Income in Millions 78 -19 19 -48 -43
Y / Y Net Income Growth - - - - -
Annual Return On Investment 6.74 % -1.7 % 2.47 % -7.25 % -6.23 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 6.74 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ANIP's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ANIP's Competitors
Subscribers only: Roi for Ani Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ANIP's Customers

Other Ratios
ANIP's Roa ANIP's Inventory Turnover Ratio ANIP's Growth Rates ANIP's Dividend Statistics
ANIP's Profitability Ratios ANIP's Asset Turnover Ratio ANIP's Dividend Growth
ANIP's Roe ANIP's Valuation Ratios ANIP's Financial Strength Ratios ANIP's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %
3m Company  13.24 %
Beone Medicines Ltd   13.17 %
Regeneron Pharmaceuticals Inc   13.00 %
Abbvie Inc   12.87 %
Lantheus Holdings Inc   11.96 %
Msa Safety Inc  11.78 %
Inspire Medical Systems inc   11.63 %
Transmedics Group Inc   11.55 %

Date modified: 2026-11-09T06:44:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.